516 related articles for article (PubMed ID: 28432455)
1. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
2. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
[TBL] [Abstract][Full Text] [Related]
3. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.
Butterfield JSS; Biswas M; Shirley JL; Kumar SRP; Sherman A; Terhorst C; Ling C; Herzog RW
Hum Gene Ther Methods; 2019 Jun; 30(3):81-92. PubMed ID: 31140323
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
Triozzi PL; Aldrich W; Ponnazhagan S
Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
6. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
Johnson TR; Rao S; Seder RA; Chen M; Graham BS
Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases.
Mitchell D; Olive C
Mol Immunol; 2010 Jul; 47(11-12):2065-73. PubMed ID: 20451253
[TBL] [Abstract][Full Text] [Related]
9. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
10. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide.
Chen L; Arora M; Yarlagadda M; Oriss TB; Krishnamoorthy N; Ray A; Ray P
J Immunol; 2006 Aug; 177(4):2373-83. PubMed ID: 16887999
[TBL] [Abstract][Full Text] [Related]
11. Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.
van Haren SD; Dowling DJ; Foppen W; Christensen D; Andersen P; Reed SG; Hershberg RM; Baden LR; Levy O
J Immunol; 2016 Dec; 197(11):4413-4424. PubMed ID: 27793997
[TBL] [Abstract][Full Text] [Related]
12. Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production.
Berghöfer B; Haley G; Frommer T; Bein G; Hackstein H
J Immunol; 2007 Apr; 178(7):4072-9. PubMed ID: 17371961
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
14. Activation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.
Haas F; Yamauchi K; Murat M; Bernasconi M; Yamanaka N; Speck RF; Nadal D
J Virol; 2014 Sep; 88(17):10002-12. PubMed ID: 24942583
[TBL] [Abstract][Full Text] [Related]
15. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
16. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M
Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101
[TBL] [Abstract][Full Text] [Related]
18. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
[TBL] [Abstract][Full Text] [Related]
19. IL-4 suppresses the responses to TLR7 and TLR9 stimulation and increases the permissiveness to retroviral infection of murine conventional dendritic cells.
Sriram U; Xu J; Chain RW; Varghese L; Chakhtoura M; Bennett HL; Zoltick PW; Gallucci S
PLoS One; 2014; 9(1):e87668. PubMed ID: 24489947
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]